Compare Smith & Nephew plc (SNN) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.11 (market cap $46.41B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 4.2× Smith & Nephew plc's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays the higher dividend (4.68%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Vivmark Residential Common Shares of Beneficial Interest for 1 Days on average.
| SNN | VMRK | |
|---|---|---|
Market Cap | $11.10B | $46.41B |
Volume | 1,051,703 | 6,584,008 |
Sector | Health | Real Estate |
52-Week High | $37.17 | $70.15 |
52-Week Low | $26.42 | $57.98 |
Typical Hold Time | 121 Days | 1 Days |
Enterprise Value | $14.13B | $55.52B |
Dividend Yield | 2.95% | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
